Welcomed Dr. Xiantang Li joins Taichu Bio as a Senior Pathologist.

On March 28, 2023, AceMab and Jinyu Boworunze Biotechnology (referred to as Jinyu Biotechnology) announced a strategic partnership, jointly committed to the development of therapeutic all human dual antibody drugs.

Suzhou, March 16, 2023. Mr. Oskar Gold, Senior Vice President, Asia Pacific and Global Emerging Markets at Vetter, and Mr. Daniel Zhang, Head of Marketing China at Vetter, visited Tarlead Biologic's Suzhou facility.

Shanghai Taichu Biotechnology Co., Ltd. (Taichu Bio) has completed the preliminary establishment and preparation for its Drug Non-Clinical Safety Evaluation segment. Effective March 1, 2023, the segment will commence a comprehensive trial operation in full compliance with the Good Laboratory Practice (GLP) regulations.

Suzhou, March 1, 2023 – Tarlead Biologics (Suzhou) Co., Ltd. ("Tarlead Biologics") held its grand opening ceremony today at the Suzhou BioBay Industrial Park. Over sixty industry experts, investors, park leaders, and senior media representatives attended the event, collectively witnessing this significant milestone in Tarlead Biologics' development.

Honored at the Shanghai Bio-Forum by industry groups and Huayi Research, AceMab was recognized for its strong growth potential in the CXO field (CRO/CDMO/CMO) amidst industry challenges. CEO Dr. Li Jianliang accepted the award.

Taichu Group and Ubrigene announced a strategic collaboration on July 15, 2022, to jointly advance China's CGT industry. Combining Taichu Bio's integrated CRDMO services and facilities with Ubrigene's leading viral vector CDMO expertise and global presence, the partnership aims to provide clients with comprehensive solutions, including "China-US/EU dual IND submissions" and clinical trial support. This alliance leverages both parties' strengths to offer integrated, end-to-end services, accelerating the development and global expansion of China's CGT sector.